Novacyt (STU:NYZ) FCF Margin % : -175.64% (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Novacyt FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Novacyt's Free Cash Flow for the six months ended in Jun. 2023 was €-6.83 Mil. Novacyt's Revenue for the six months ended in Jun. 2023 was €3.89 Mil. Therefore, Novacyt's FCF Margin % for the quarter that ended in Jun. 2023 was -175.64%.

As of today, Novacyt's current FCF Yield % is -40.42%.

The historical rank and industry rank for Novacyt's FCF Margin % or its related term are showing as below:

STU:NYZ' s FCF Margin % Range Over the Past 10 Years
Min: -228.97 Med: -36.08 Max: 36.72
Current: -228.97

During the past 12 years, the highest FCF Margin % of Novacyt was 36.72%. The lowest was -228.97%. And the median was -36.08%.

STU:NYZ's FCF Margin % is ranked worse than
83.89% of 832 companies
in the Medical Devices & Instruments industry
Industry Median: -7.45 vs STU:NYZ: -228.97

Novacyt FCF Margin % Historical Data

The historical data trend for Novacyt's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novacyt FCF Margin % Chart

Novacyt Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-14.07

-9.99

36.72

12.52

-67.23

Novacyt Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial															-27.24	63.87	-11.89	-268.80	-175.64

Competitive Comparison of Novacyt's FCF Margin %

For the Medical Devices subindustry, Novacyt's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novacyt's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Novacyt's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Novacyt's FCF Margin % falls into.

Novacyt FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Novacyt's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-16.264	/	24.192
	=	-67.23 %

Novacyt's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-6.834	/	3.891
	=	-175.64 %

Novacyt FCF Margin % Related Terms

Thank you for viewing the detailed overview of Novacyt's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Novacyt (STU:NYZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Novacyt SA (STU:NYZ) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NVYTF:USA NCYT:UK ALNOV:France NYZ:Germany

Address

13, Avenue Morane Saulnier, Velizy-Villacoublay, FRA, 78140

Website

https://www.novacyt.com

Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Novacyt (STU:NYZ) Headlines

No Headlines